One difference is that they have a change to a gene called MYC. Telling these two cancers apart is important, because the treatments are different. Lymphoplasmacytic lymphoma is a rare and slow ...

The drug has promising data in hand in diffuse large B cell lymphoma (DLBCL), a form of non ... two well-established genes linked to cancer – MYC and MCL1 – which have traditionally been ...

The inclusion criteria for patients were as follows: (1) no previous chemotherapy or targeted therapy; (2) pathologically confirmed DLBCL exhibiting co-expression of MYC (≥40%) and BCL2 (>50%) (2, 4); ...

Scientists suggest understanding ecDNA’s role in pancreatic cancer could potentially guide future strategies for making tumors more vulnerable to treatment.

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

A rare case has been reported of diffuse large B-cell lymphoma (DLBCL) presenting initially as cold agglutinin disease (CAD). The report, published in the Kaohsiung Journal of Medical Sciences, ...

What Is B-Cell Lymphoma? B-cell lymphoma is a cancer that forms in your white blood cells called lymphocytes. These cells are made by your lymphatic system, which plays an important role in immunity.

DelveInsight's Molecular Glues Market Insights report includes a comprehensive understanding of current treatment practices, ...

About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...